Press Release,
Revenue and Result
The item other external costs of 2.9 MSEK consists of costs for purchased services of 0,7 MSEK and various other costs of 2.2 MSEK.
Financial Position
During the period, the company has received cash of 3.8 MSEK from an extended loan from
In order to solve the Company's longer-term financing needs, Realheart works continuously to evaluate alternatives for further capitalization of the Company.
Significant Events During the Second Quarter of the Year
In April, it is announced that industry players and Realheart estimate the market potential for total artificial hearts (TAHs) to be over 200,000 units per year in
During April, the company announces that
Furthermore, it is communicated that results of Scandinavian Realheart's total artificial heart showing lower hemolysis are published in the journal Artificial Organs. The article summarizes the work done by an international research team led by Dr
May begins with researchers at
In mid-May, Realheart communicates decisions on new issues of up to 73 MSEK. May also includes a confirmation that
June begins with a board member resigning from
In the beginning of June, Realheart announces that the company participates in a Vinnova collaboration for wireless TAH technology. The company Invivopower has been awarded a grant of 0.9 MSEK from Vinnova to further develop its patented technology for wireless energy transfer through the skin in collaboration with
In mid-June, cardiac surgeon Dilek Gürsoy speaks about Realheart's artificial heart at Impact LECH. Gürsoy, who is one of several first-class speakers, talks about artificial hearts in general and about Realheart's artificial heart specifically. She also participates in a panel discussion on "Man and machine in medicine".
During the second half of June, Realheart publishes a prospectus in connection with a rights issue of units of approximately 56 MSEK. The subscription period in the Rights Issue runs from
At the end of June, Realheart communicates that the Company's Chief Medical Officer Dr.
Among the last things to happen in June is the approved trademark registration of Realheart in key international markets, in addition to the protection that the brand already has in
Significant Events After the End of the Period
In the first days of July, the Company communicates that
July also begins with the German heart surgeon Professor
In the first week of July, after
Further into July,
At the end of July, a press release is published that Realheart conducts a directed new issue of units to guarantors and a directed issue to EIC in connection with the completed rights issue.
A few days into August, Realheart announces the last day of trading with BTU and the first day of trading with warrants of series TO2.
In the second week of August, Realheart communicates that Magnus Öhman is elected to the company's board of directors. Magnus Öhman has extensive experience from the medical technology industry, including as CEO of St. Jude Medical's Swedish subsidiary within Cardiac Rhythm Management.
CEO Ina Laura Perkins has the Word
A look back at the first quarter provides confidence in the development going forward, including the achievement of a significant milestone of four-day survival in animals. Confidence in the product and the company was strengthened, resulting in two prominent cardiac surgeons deciding to join our team; Professor
During the second quarter, the initial focus was on intensified marketing towards the medical community via three articles on Realheart® TAH, approved for publication in scientific journals. Later in the quarter, we increased awareness of our heart among our collaborating cardiac surgeons and the general public through a news broadcast at
As we establish an internationally recognized brand, it is of course important to ensure its protection. We are therefore delighted to announce that Realheart is registered in several key target markets, including the EU, US,
On the financing side, we got the go-ahead from the
Another exciting news is the collaboration with the Swedish Invivopower for the development of wireless charging instead of power supply via a cable through the skin, which is the norm for all heart pump manufacturers today. The Vinnova funding enables Invivopower to develop a first prototype for wireless charging completely tailored to our wishes. This is a great opportunity for us to start a future project in the present and thus potentially offer wireless charging earlier than planned. This would benefit both patients and doctors.
Our request to Sahlgrenska for collaboration to conduct the first clinical trial received a very positive response from Professor Göran Dellgren, an internationally recognized heart surgeon. The hospital is one of only two in
VD,
Scandinavian Real Heart AB
Swedish innovation power has given the world medical technology inventions such as the heart and lung machine, the pacemaker and the dialysis machine. The next big innovation is Realheart's artificial heart. A Swedish patented innovation that will save the lives of heart failure patients. Every year, 3,500 people die of heart failure in
The start-up of the company was initiated by the doctor
Patent Protection
Realheart has granted patents in
Patent protection is also available on the latest version of Realheart® TAH in
Finally, the patent application has been filed in two parts for the use of pressure sensors for the automatic control. Given the existing patents together with the new patent applications, the Board believes that the company has a strong patent situation and strong intellectual property protection.
Mission and Goal
Realheart's mission is to use medical technology solutions to save as many heart failure patients as possible and to create the best conditions for a life-affirming continuation of life. The company's overall goal is for the artificial heart to be commercialized and become a full-fledged treatment alternative for patients with heart failure. The heart should have a better function than the solutions that are on the market today. It should be possible to use both as a bridge to transplantation and as final therapy.
The Stock
Principles for the Preparation of the Interim Report
The interim report has been prepared in accordance with the Annual Accounts Act and with the application of general advice, recommendations and statements from the
Audit Review
The interim report has not been reviewed by the Company's auditor.
Upcoming Financial Reports
Interim Report Q3, 2023 2022-11-16
Year-end Report, 2023 2023-02-15
Annual General Meeting
The company's annual general meeting is planned
to be held Thursday, June13th, 2024.
Submission of Interim Report
Västerås,
The Board
For Further Information, Please Contact
CEO
Phone: +46 70 406 49 21
E-mail: inalaura.perkins@realheart.se
CFO
Phone: +46 70 643 88 61
E-mail: jonas.bark@realheart.se
This disclosure contains information that Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information in this press release has been published through the agency of the contact persons set out below, at the time stated by
Link to archive for financial reports: https://realheart.se/sv/investerare/arkiv/
https://news.cision.com/real-heart/r/interim-report-230401-230630,c3820860
https://mb.cision.com/Main/12118/3820860/2247001.pdf
https://mb.cision.com/Public/12118/3820860/89e56888246ff076.pdf
(c) 2023 Cision. All rights reserved., source